About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid

Clinicaltrials.gov identifier NCT03926377

Recruitment Status Not yet recruiting

First Posted April 24, 2019

Last update posted April 24, 2019

Study Description

Brief summary:

Bullous pemphigoid is the most common type of bullous skin disease and is clinically characterized by clear-tense bullae, which result in post-bullous cutaneous erosions, altering the skin barrier. The treatment of this pathology consists of the application of high doses of topical corticosteroids (clobetasol propionate) for a prolonged period of at least 6 months. The main objective of this study is to demonstrate a change in bone mineral density at 6 months after initiation of treatment, in subjects with bullous pemphigoid and treated with topical corticosteroid.

  • Condition or Disease:Osteoporosis
    Bullous Pemphigoid
  • Intervention/Treatment: Procedure: bone densitometry
    Biological: blood test
    Procedure: radiographs of the thoracic and lumbar spine
    Procedure: Clobetasol propionate
  • Phase: Phase 4
Detailed Description

Glucocorticoids have direct effects on bone remodeling by suppressing bone formation (inhibition of osteoblastic differentiation, inhibition of mature osteoblasts function and apoptosis of mature osteoblasts) and by increasing bone resorption (decrease in osteoclast apoptosis and stimulation of osteoclastogenesis). They also have indirect bone effects by decreasing the intestinal absorption of calcium and increasing its urinary excretion, and by inhibiting the somatotropic and gonadotropic axis. This pathophysiology results in excessive bone fragility. Bone loss and increased incidence of fractures occur within 6 months after the introduction of oral corticosteroid therapy, with a partially reversible phenomenon within months of discontinuation. The extent of bone loss depends on the dose and duration of glucocorticoid administration. The systemic transition of topical corticosteroids depends on several parameters such as excipients, anatomical location, cutaneous state, the dose used and the duration of exposure. Clobetasol propionate, used for long-term use in bullous pemphigoid, is a Class IV dermocorticoid (highly potent). Patients with bullous pemphigoid will benefit from bone densitometry at the initiation of treatment, at 3 months (theoretical end of the treatment of attack) and at 6 months (theoretical end of the treatment). Patients will also benefit a blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8 to highlight possible correlations between changes in bone mineral density and phosphocalcic parameters and 8 cortisolemia (braking of the hypothalamic-pituitary-adrenal axis). Patients will also benefit from standard radiographs of the thoracic and lumbar spine at the initiation of treatment and at 6 months. Follow-up is planned over 6 months, with 2 follow-up visits at 3 months and 6 months.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 50 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid
  • Estimated Study Start Date: April 2019
  • Estimated Primary Completion Date: October 2020
  • Estimated Study Completion Date: April 2021
Arms and interventions
Arm Intervention/treatment
Other: Clobetasol propionate treatment
Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
Procedure: bone densitometry
Patients with bullous pemphigoid will benefit from bone densitometry at the initiation of treatment, at 3 months (theoretical end of the treatment of attack) and at 6 months (theoretical end of the treatment).

Biological: blood test
Blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8 hours to highlight possible correlations between changes in bone mineral density and phosphocalcic parameters and 8 hours cortisolemia.

Procedure: radiographs of the thoracic and lumbar spine
standard radiographs of the thoracic and lumbar spine will be done at the initiation of treatment and at 6 months.

Procedure: Clobetasol propionate
Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
Outcome Measures
  • Primary Outcome Measures: 1. Variation of the bone mineral density (BMD) expressed in g/cm² at the lumbar spine between baseline and the theorical end of the treatment. [ Time Frame: 6 months after beginning of the treatment ]
    Patients with bullous pemphigoid and treated with Clobetasol propionate will benefit from bone densitometry at the initiation of the treatment and at 6 months (theoretical end of the treatment).
  • Secondary Outcome Measures: 1. Variation of the bone mineral density (BMD) expressed in g/cm² at the lumbar spine between baseline and the theorical end of the treatment of attack. [ Time Frame: 3 months after beginning of the treatment ]
    Patients with bullous pemphigoid and treated with Clobetasol propionate will benefit from bone densitometry at the initiation of the treatment and at 3 months (theoretical end of the treatment of attack).
  • 2. Variation of the bone mineral density (BMD) expressed in g/cm² at the hip between baseline and the theorical end of the treatment of attack. [ Time Frame: 3 months after beginning of the treatment ]
    Patients with bullous pemphigoid and treated with Clobetasol propionate will benefit from bone densitometry at the hip at the initiation of the treatment and at 3 months (theoretical end of the treatment of attack).
  • 3. Variation of the bone mineral density (BMD) expressed in g/cm² at the hip between baseline and the theorical end of the treatment. [ Time Frame: 6 months after beginning of the treatment ]
    Patients with bullous pemphigoid and treated with Clobetasol propionate will benefit from bone densitometry at the hip at the initiation of the treatment and at 6 months (theoretical end of the treatment).
  • 4. Variation in plasma concentrations of corrected calcemia, phosphoremia, 25 OH vitamin D and cortisolemia between Baseline and the theorical end of the treatment of attack. [ Time Frame: 3 months after beginning of the treatment ]
    Patients with bullous pemphigoid and treated with Clobetasol propionate will benefit from a blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8h at the initiation of the treatment and at 3 months (theoretical end of the treatment attack).
  • 5. Variation in plasma concentrations of corrected calcemia, phosphoremia, 25 OH vitamin D and cortisolemia between Baseline and the theorical end of the treatment. [ Time Frame: 6 months after beginning of the treatment ]
    Patients with bullous pemphigoid and treated with Clobetasol propionate will benefit from a blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8h at the initiation of the treatment and at 6 months (theoretical end of the treatment).
  • 6. frequency of fractures (axial and , or peripheral) [ Time Frame: 6 months after beginning of the treatment ]
    Patients with bullous pemphigoid and treated with Clobetasol propionate will benefit from standard radiographs of the thoracic and lumbar spine at the initiation of the treatment and at 6 months (theoretical end of the treatment).
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- patients presenting a multi-bullous pemphigoid newly diagnosed or relapsed more than 3
months after stopping corticosteroids and treated according to the national protocol
for diagnosis and care issued by the reference center for autoimmune bullous diseases
of April 2016

- patients having received written and oral information and signed informed consent

- patients covered by national health insurance

Exclusion Criteria:

- Patients under tutorship or curatorship or inability to give informed consent

- Patients receiving an anti-osteoporotic treatment

- Patients requiring an anti-osteoporotic baseline treatment (T-score ⩽ -3DS on at least
1 site or FRAX score above the therapeutic intervention threshold)

- Patients with one or more major risk factors for osteoporosis

- Patients who have received topical corticosteroids in less than 3 months

Contacts and Locations
Contacts

Contact: Benjamin Batteux, MD (33)322088370 batteux.benjamin@chu-amiens.fr

Contact: Guillaume Chaby, MD (33)322455846 chaby.guillaume@chu-amiens.fr

Locations
Sponsors and Collaborators

Centre Hospitalier Universitaire, Amiens

University Hospital, Rouen

Investigators

Principal Investigator: Guillaume Chaby, MD CHU Amiens

Principal Investigator: Catherine Lok, Pr CHU Amiens

Principal Investigator: Pascal Joly, Pr CHU Amiens

More Information
  • Responsible Party: Centre Hospitalier Universitaire, Amiens
  • ClinicalTrials.gov Identifier: NCT03926377 History of Changes
  • Other Study ID Numbers: PI2018_843_0040
  • First Posted: April 24, 2019 Key Record Dates
  • Last Update Posted: April 24, 2019
  • Last Verified: April 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Centre Hospitalier Universitaire, Amiens: osteoporosis
    dermocortocoids
    bullous pemphigoid
    pharmacoepidemiology
  • Additional relevant MeSH terms: Osteoporosis Pemphigoid, Bullous